TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
aTyr Pharma ( (ATYR) ) has issued an announcement.
On December 4, 2025, aTyr Pharma, Inc. received a deficiency notice from Nasdaq, indicating that its stock price had fallen below the required $1.00 per share for 30 consecutive business days. This notice does not immediately affect the company’s listing, and aTyr Pharma has until June 2, 2026, to comply with the minimum bid price requirement. The company is exploring options to regain compliance, including a potential reverse stock split, to avoid delisting.
The most recent analyst rating on (ATYR) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on aTyr Pharma stock, see the ATYR Stock Forecast page.
Spark’s Take on ATYR Stock
According to Spark, TipRanks’ AI Analyst, ATYR is a Underperform.
aTyr Pharma’s overall stock score is primarily impacted by its challenging financial performance, characterized by ongoing losses and negative cash flows. Technical analysis indicates bearish momentum, with the stock trading below key moving averages and oversold conditions. The negative P/E ratio further highlights valuation concerns. These factors collectively contribute to a low overall score, reflecting significant risks and challenges facing the company.
To see Spark’s full report on ATYR stock, click here.
More about aTyr Pharma
Average Trading Volume: 10,817,705
Technical Sentiment Signal: Sell
Current Market Cap: $81.11M
For a thorough assessment of ATYR stock, go to TipRanks’ Stock Analysis page.